Using validated agonistic small molecule compounds, we showed that GPR65 stimulation resulted in the efficient inhibition of T-cell effector functions upon activation by tumour cells bearing natural levels of peptide/HLA antigens, similar to what T-cells may encounter in the context of an immune response to a patient tumour. This evidence concerns the gene GPR65 and neoplasm.